Evidence map›Paper›PMID 35189854›Full record

ArticleBMC neurology2022

Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset.

Harper S Kim, John Son, Donghwan Lee, Joy Tsai, Danny Wang, E Sandra Chocron, Seongwoo Jeong, Pamela Kittrell, Charles F Murchison, Richard E Kennedy and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Review
  16. Review
  17. Alteration of salivaryFrontiers in pharmacology · 2025
    Article
  18. Review
  19. Article
  20. Gut microbiota immune cross-talk in amyotrophic lateral sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Harper S KimCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
John SonDepartment of Anesthesiology, University of California Irvine, Irvine, CA, USA.
Donghwan LeeSchool of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Joy TsaiSchool of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Danny WangSchool of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.
E Sandra ChocronBarshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, USA.
Seongwoo JeongSchool of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Pamela KittrellDepartment of Neurology, University of Texas Health San Antonio, San Antonio, TX, USA.
Charles F MurchisonCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Richard E KennedyCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Alejandro TobonDepartment of Neurology, South Texas Veteran Health Care System, San Antonio, TX, USA.
Carlayne E JacksonDepartment of Neurology, University of Texas Health San Antonio, San Antonio, TX, USA.
Andrew M PickeringCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. ampickering@uabmc.edu.
The University of Texas Health Science Center at San Antonio · USUniversity of Alabama at Birmingham · USThe University of Texas at San Antonio · USLongevity Biotech (United States) · USMassachusetts General Hospital · USSouth Texas Veterans Health Care System · USStanford University · USUniversity of California, Irvine · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8M
TRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4M
Biological and environmental factors driving behavioral symptoms in Alzheimer's diseaseR01MH121928 · NIMH · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PICKERING, ANDREW MICHAEL, PICKERING, CAROLYN E ZIMINSKI · 2019 to 2024
$2.9M
Proteasome dysfunction as a driver of age-associated risk for Alzheimer's disease onset and progressionRF1AG065301 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PICKERING, ANDREW MICHAEL · 2020 to 2020
$2.1M
Dissecting the Interplay between proteasome dysfunction, proteostasis and Alzheimer's diseaseR56AG061051 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PICKERING, ANDREW MICHAEL · 2018 to 2019
$1.5M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
NIA NIH HHS R56 AG061051NIA NIH HHS RF1 AG065301NIA NIH HHS T32 AG021890NIGMS NIH HHS T32 GM008361NIGMS NIH HHS T32 GM113896NIH HHS R56AG061051, T32AG021890, T32GM008361-28, T32GM113896,
6 · The paper itself

Abstract

backgroundPrior studies on the role of gut-microbiome in Amyotrophic Lateral Sclerosis (ALS) pathogenesis have yielded conflicting results. We hypothesized that gut- and oral-microbiome may differentially impact two clinically-distinct ALS subtypes (spinal-onset ALS (sALS) vs. bulbar-onset ALS (bALS), driving disagreement in the field.

methodsALS patients diagnosed within 12 months and their spouses as healthy controls (n = 150 couples) were screened. For eligible sALS and bALS patients (n = 36) and healthy controls (n = 20), 16S rRNA next-generation sequencing was done in fecal and saliva samples after DNA extractions to examine gut- and oral-microbiome differences. Microbial translocation to blood was measured by blood lipopolysaccharide-binding protein (LBP) and 16S rDNA levels. ALS severity was assessed by Revised ALS Functional Rating Scale (ALSFRS-R).

resultssALS patients manifested significant gut-dysbiosis, primarily driven by increased fecal Firmicutes/Bacteroidetes-ratio (F/B-ratio). In contrast, bALS patients displayed significant oral-dysbiosis, primarily driven by decreased oral F/B-ratio. For sALS patients, gut-dysbiosis (a shift in fecal F/B-ratio), but not oral-dysbiosis, was strongly associated with greater microbial translocation to blood (r = 0.8006, P < 0.0001) and more severe symptoms (r = 0.9470, P < 0.0001). In contrast, for bALS patients, oral-dysbiosis (a shift in oral F/B-ratio), but not gut-dysbiosis, was strongly associated with greater microbial translocation to blood (r = 0.9860, P < 0.0001) and greater disease severity (r = 0.9842, P < 0.0001). For both ALS subtypes, greater microbial translocation was associated with more severe symptoms (sALS: r = 0.7924, P < 0.0001; bALS: r = 0.7496, P = 0.0067). Importantly, both sALS and bALS patients displayed comparable oral-motor deficits with associations between oral-dysbiosis and severity of oral-motor deficits in bALS but not sALS. This suggests that oral-dysbiosis is not simply caused by oral/bulbar/respiratory symptoms but represents a pathological driver of bALS.

conclusionsWe found increasing gut-dysbiosis with worsening symptoms in sALS patients and increasing oral-dysbiosis with worsening symptoms in bALS patients. Our findings support distinct microbial mechanisms underlying two ALS subtypes, which have been previously grouped together as a single disease. Our study suggests correcting gut-dysbiosis as a therapeutic strategy for sALS patients and correcting oral-dysbiosis as a therapeutic strategy for bALS patients.

Indexed as

Amyotrophic Lateral SclerosisGastrointestinal MicrobiomeDysbiosisHumansRNA, Ribosomal, 16SSeverity of Illness IndexRNA, Ribosomal, 16SAmyotrophic lateral sclerosisLou Gehrig’s diseaseMicrobiome

Identifiers

PMID35189854
PMCPMC8862222
OpenAlexW4213263372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.